These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25421050)

  • 1. Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".
    Chin PK; Wright DF; Florkowski CM
    Circulation; 2014 Nov; 130(22):e194. PubMed ID: 25421050
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Nov; 130(22):e195. PubMed ID: 25421051
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACP Journal Club. In atrial fibrillation, dabigatran had similar efficacy to warfarin but caused less bleeding in higher GFR.
    Sarvananthan S; Punjabi PP
    Ann Intern Med; 2014 Aug; 161(4):JC7. PubMed ID: 25133386
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Reiffel JA
    Circulation; 2012 Jan; 125(3):e292; author reply e293-4. PubMed ID: 22271858
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Reynolds S; Parra D; Rosenstein RS
    Circulation; 2012 Jan; 125(3):e291; author reply e293-4. PubMed ID: 22271857
    [No Abstract]   [Full Text] [Related]  

  • 7. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
    Nagarakanti R; Ezekowitz MD; Oldgren J; Yang S; Chernick M; Aikens TH; Flaker G; Brugada J; Kamensky G; Parekh A; Reilly PA; Yusuf S; Connolly SJ
    Circulation; 2011 Jan; 123(2):131-6. PubMed ID: 21200007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter by Stollberger and Finsterer regarding article, "intracranial hemorrhage in patients with atrial fibrillation during anticoagulation with Warfarin or Dabigatran: the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial".
    Stöllberger C; Finsterer J
    Stroke; 2012 Sep; 43(9):e93. PubMed ID: 22764210
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Govindarajan R; Salgado E
    Circulation; 2012 Jan; 125(3):e290; author reply e293-4. PubMed ID: 22271856
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".
    Freeman WD; Kuo R; Aguilar MI
    Stroke; 2012 Jul; 43(7):e63. PubMed ID: 22618385
    [No Abstract]   [Full Text] [Related]  

  • 11. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
    Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
    Flaker G; Ezekowitz M; Yusuf S; Wallentin L; Noack H; Brueckmann M; Reilly P; Hohnloser SH; Connolly S
    J Am Coll Cardiol; 2012 Feb; 59(9):854-5. PubMed ID: 22361407
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
    Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
    J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.
    Böhm M; Ezekowitz MD; Connolly SJ; Eikelboom JW; Hohnloser SH; Reilly PA; Schumacher H; Brueckmann M; Schirmer SH; Kratz MT; Yusuf S; Diener HC; Hijazi Z; Wallentin L
    J Am Coll Cardiol; 2015 Jun; 65(23):2481-93. PubMed ID: 26065986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
    Hjemdahl P; Johnsson H; Wallén NH
    Circulation; 2013 Mar; 127(11):e505. PubMed ID: 23509038
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
    David JS; Piriou V; Albaladejo P
    Circulation; 2013 Mar; 127(11):e504. PubMed ID: 23509037
    [No Abstract]   [Full Text] [Related]  

  • 20. Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.
    DiNicolantonio JJ
    Expert Opin Pharmacother; 2012 Jun; 13(8):1101-11. PubMed ID: 22435606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.